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Since 2005 all new glucose-lowering medicines to be used in Europe have required approval by the 
European Medicines Agency (EMA) through a centralised procedure [1].  This involves assessment of 
a detailed file of data generated during the preclinical studies and phase 1-3 clinical trials, along with 
the proposed product label.  The file is subject to internal review and some aspects may also receive 
external review, giving rise to questions that are referred back to the sponsor and may lead to 
additional studies.  The assessment is considered by the Committee for Medicinal Products for 
Human Use (CHMP) and if approval is recommended then a marketing authorisation is usually 
granted by the European Commission.  Use within individual countries may also involve the 
competent authority of that country to implement the conditions of the marketing authorisations as 
well as the price setting.  Further endorsements may be required by other national bodies such as 
NICE in the UK.  Meanwhile post-approval studies mandated by the regulators or undertaken on the 
initiative of the sponsor, such as cardiovascular outcome trials, will be monitored and considered for 
any amendments to the label.  At the same time the Eudravigilance system will collect safety reports 
and consider signals for adverse effects. 
New drug assessments take account of unmet need, existing therapies, properties of the new agent, 
the quality and extent of information submitted, and the intended use  -  with safety as a crucial 
element. The review by Blind et al documents the variety of new glucose-lowering agents for type 2 
diabetes approved by EMA since 2005 [2].  These agents conform to guidance set out by EMA in 
2002 and 2012 [3], and are predated by metformin, sulfonylureas, meglitinides, pioglitazone, alpha-
glucosidase inhibitors and insulins that were already available before 2005.  An updated guidance 
document from EMA on agents to treat or prevent diabetes mellitus is planned for introduction in 
2018.  
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Risk-benefit is the guiding principle of the assessment process.  It is often a delicate and sometimes 
unquantifiable balancing exercise which includes what (in another context) Donald Rumsfeld 
described as the known unknowns and the unknown unknowns [4].  The former might include an 
aspect not tested in the human trials such as overdose or use in pregnancy, while the latter could be 
a drug interaction not encountered during the pre-approval trials and not anticipated on theoretical 
grounds.  Some risks such as hypoglycaemia are well recognised and must be commensurate with 
the benefits. With regard to insulins for example hypoglycaemia is an accepted risk for this essential 
life-support therapy, appreciating that reasonable cautions are undertaken to minimise such risk.   
The need for a variety of differently acting glucose-lowering agents is consistent with the many 
different causative and exacerbating components of type 2 diabetes that contribute to its 
heterogeneous and progressive pathophysiology [5].   Treatment often requires more than one 
agent, hence the variety of combination products approved by EMA which include fixed-dose 
combination tablets and fixed-ratio injectable combinations.  Several studies have demonstrated the 
potential benefits of a combination approach to achieve early, effective and sustained glycaemic 
control in type 2 diabetes, as acknowledged in the treatment algorithms [6, 7].    
The use of HbA1c as a surrogate marker of metabolic effectiveness to mitigate diabetic 
complications comes under the spotlight periodically, but seems set to stay.  Other measures of 
glycaemic control including glucose variability are informative but they are more difficult to assess 
with consistency, and waiting for complications in pre-approval trials is ethically unpalatable given 
current knowledge of the detriments of glucotoxicity.   
Guidance for sponsors is under review at EMA, but the record of agents approved since 2005 
indicates a thorough and responsive review process with follow-up amendments to the drug label as 
new evidence arises, enabling safer and/or wider use of agents in a timely manner [8].  It is noted 
that EMA and FDA do not always derive the same conclusions from the same information: opinions 
of advisory committees can differ, and regulators may take account of the availability of other 
medicines, the requirements of different populations, historical factors and levels of uncertainties.  
Consultation with experienced reviewers is important to help to interpret new data.  
For the future the regulatory process may expand attention on preventative measures, take 
advantage of advances in pharmacogenomics to refine drug labels and consider further 
opportunities for the integration of comprehensive glucose monitoring and automated drug 
delivery.   
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